Standalone Financial Results (Rs. in Lakhs)

Income:

  • Net Sales/Income from operations: ₹4,091.20 (vs ₹7,196.88 in Q4 FY2026; ₹3,412.20 in Q1 FY2026)
  • Other Income: ₹354.76 (vs ₹113.63 in Q4 FY2026; ₹349.52 in Q1 FY2026)
  • Total Income: ₹4,445.96 (vs ₹7,310.51 in Q4 FY2026; ₹3,761.72 in Q1 FY2026)

Expenses:

  • Cost of Materials Consumed: ₹2,024.54
  • Changes in Inventories: (₹19.81)
  • Employee Benefit Expenses: ₹352.50
  • Finance Cost: ₹48.63
  • Depreciation and Amortisation: ₹75.86
  • Export Product Registration/Commission: ₹749.66
  • Other Expenses: ₹1,365.41
  • Total Expenses: ₹3,751.16

Profitability:

  • Profit before Exceptional Items: ₹694.80
  • Exceptional Items: ₹2
  • Profit before Tax: ₹694.80
  • Tax Expenses: Current Tax ₹161.17, Deferred Tax ₹28.38
  • Net Profit after Tax: ₹505.24
  • Other Comprehensive Income: ₹500.21
  • Total Comprehensive Income: ₹1,005.46

Capital Structure:

  • Paid-up equity share capital: ₹3,496.16 (Face Value ₹10 per share)
  • Earnings per share (Basic and Diluted): ₹1.45

Consolidated Financial Results (Rs. in Lakhs)

Income:

  • Net Sales/Income from Operations: ₹4,487.89
  • Other Income: ₹289.69
  • Total Income: ₹4,777.58

Expenses:

  • Cost of Materials Consumed: ₹2,015.40
  • Changes in inventories: (₹19.81)
  • Employee Benefit Expenses: ₹413.63
  • Finance Cost: ₹87.64
  • Depreciation and Amortisation: ₹109.33
  • Export Product Registration/Commission: ₹1,977.00
  • Other expenses: ₹889.16
  • Total Expenses: ₹4,391.29

Profitability:

  • Profit before Exceptional Items: ₹386.29
  • Profit before Tax: ₹386.29
  • Tax Expenses: Current Tax ₹161.17, Deferred Tax ₹28.38
  • Profit after tax from continuing operations: ₹196.74
  • Other Comprehensive Income: ₹500.21
  • Total Comprehensive Income: ₹696.95

Attribution:

  • Net Profit attributable to: Owners ₹291.30, Non-Controlling Interest (₹94.56)
  • Total Income attributable to: Owners ₹791.51, Non-Controlling Interest (₹94.56)
  • Earnings per Share (Basic): ₹0.83

Subsidiary Information

The consolidated results include:

1. Monarchy Healthserve Private Limited - Not reviewed by auditors, reported total revenues of ₹Nil, Net Loss after tax of ₹(22.00) Lakhs, total comprehensive loss of ₹(22.00) Lakhs

2. Kilitch Estro Biotech PLC (Foreign Subsidiary) - Based on management-certified unaudited financial statements, reported total revenues of ₹396.69 Lakhs, Net Loss after tax of ₹(286.54) Lakhs, total comprehensive loss of ₹(286.54) Lakhs

Auditor Review

C. Sharat & Associates (FRN: 128593W) conducted limited review of both standalone and consolidated results under SRE 2410. The review provides moderate assurance that the results are free from material misstatement but does not constitute an audit opinion.

Additional Information

  • The company is predominantly engaged in the pharmaceutical business with no separate reporting segments as per Ind-AS 108
  • Figures for quarter ended 31st March, 2026 are balancing figures between audited annual figures and unaudited published year-to-date figures
  • Previous period figures have been reclassified/regrouped for comparability